FGEN FibroGen Inc.

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference

SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Thane Wettig, Chief Executive Officer, will participate in a corporate presentation at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, from 3:00-3:40 PM Eastern Time. Company management will also participate in virtual one-on-one meetings with investors during the conference.

The live audio webcast of the event will be available to investors and other interested parties on the “” section of the FibroGen Investor webpage at . A replay will be available for 30 days.

About FibroGen 

FibroGen, Inc. is a biopharmaceutical company focused on accelerating the development of novel therapies at the frontiers of cancer biology. Pamrevlumab, a fully human anti-CTGF monoclonal antibody, is in clinical development for the treatment of metastatic pancreatic cancer and locally advanced unresectable pancreatic cancer (LAPC). Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. Roxadustat is in clinical development for chemotherapy-induced anemia (CIA) and a Supplemental New Drug Application (sNDA) has been accepted for review by the China Health Authority. FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of an associated CD46-targeted PET biomarker. In addition, FibroGen has expanded its research and development portfolio to include two immuno-oncology product candidates for the treatment of solid tumors. For more information, please visit .

Contacts:

FibroGen, Inc.

Investors:

David DeLucia, CFA

Vice President of Corporate FP&A / Investor Relations

Media:

Meichiel Keenan

Director, Investor Relations and Corporate Communications



EN
26/03/2024

Underlying

FGENFibroGen Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on FibroGen Inc.

 PRESS RELEASE
Free
FGEN FIBROGEN INC.

FibroGen to Participate in Upcoming Investor Conferences

FibroGen to Participate in Upcoming Investor Conferences SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the company’s management will participate in the following investor conferences: Bank of America Health Care Conference Format: 1x1 investor meetings Date: Tuesday, May 14, 2024 Location: Las Vegas, NV H.C. Wainwright 2nd Annual Bioconnect Investor Conference Format: Fireside Chat and 1x1 investor meetings Date: Monday, May 20, 2024 Fireside Chat Time: 5:00 – 5:30 PM ET Location: New York, NY The live audio webcast of the H.C....

May 7, 2024 1 EN
 PRESS RELEASE
Free
FGEN FIBROGEN INC.

FibroGen Reports First Quarter 2024 Financial Results

FibroGen Reports First Quarter 2024 Financial Results Topline data from the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in metastatic pancreatic cancer anticipated in mid-2024Topline data from LAPIS Phase 3 study in locally advanced unresectable pancreatic cancer anticipated in 3Q 2024Reported compelling data from Phase 1 monotherapy study of FG-3246, a CD46 targeted antibody drug conjugate, in metastatic castration-resistant prostate cancer First quarter net revenue growth of 55% year over year, driven by roxadustat China performance and one-time drug prod...

May 6, 2024 1 EN
 PRESS RELEASE
Free
FGEN FIBROGEN INC.

FibroGen to Report First Quarter 2024 Financial Results

FibroGen to Report First Quarter 2024 Financial Results SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2024 financial results on Monday, May 6 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Audio Webcast Interested parties may access a live audio webcast of the conference call via the “Investor Relations” page of the Company’s website at . To access the ...

April 29, 2024 1 EN
 PRESS RELEASE
Free
FGEN FIBROGEN INC.

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study o...

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that clinical data from the dose escalation portion of the Phase 1b/2 study of FG-3246 in combination with enzalutamide in patients with metastatic castration resistant prostate cancer have been selected for a poster presentation...

April 24, 2024 1 EN
 PRESS RELEASE
Free
FGEN FIBROGEN INC.

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of F...

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer FG-3246 demonstrated efficacy in adenocarcinoma selected cohorts receiving biologically active doses of FG-3246 at ≥ 1.2 mg/kg in heavily pre-treated, biomarker unselected patients: Median radiographic progression free survival of 8.7 months PSA50 response in 36% of patients Confirmed radiographic objective response rate of 20%, with a median duration of response of 7.5 months FG-3246 demonstrated an acceptable safety profi...

April 2, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch